Supernus Pharmaceuticals (SUPN) Capital Expenditures (2011 - 2025)
Supernus Pharmaceuticals' (SUPN) quarterly Capital Expenditures came in at $427000.0 in Q4 2025, up 100.47% year-on-year from $213000.0 in Q4 2024, and up 231.01% on a QoQ basis from $129000.0 in Q3 2025.
Supernus Pharmaceuticals (SUPN) Capital Expenditures (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 14 years of Capital Expenditures data on file, last reported at $427000.0 in Q4 2025.
- On a quarterly basis, Capital Expenditures rose 100.47% year-over-year to $427000.0 in Q4 2025; TTM through Mar 2026 was $1.0 million, a 25.75% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 84.55% from the prior year.
- Capital Expenditures for Q4 2025 stood at $427000.0, up from $129000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for SUPN reached as high as $549000.0 in Q1 2022 and fell as low as -$168000.0 in Q4 2022.
- Historically, Capital Expenditures has averaged $201733.3 across 4 years, with a median of $200000.0 in 2024.
- On a YoY basis, Capital Expenditures climbed as much as 691.67% in 2024 and fell as far as 59.75% in 2024.
- Year by year, Capital Expenditures stood at -$168000.0 in 2022, then surged by 78.57% to -$36000.0 in 2023, then jumped by 691.67% to $213000.0 in 2024, then soared by 100.47% to $427000.0 in 2025.
- Per Business Quant data, the three most recent Capital Expenditures figures were $427000.0 in Q4 2025, $129000.0 in Q3 2025, and $455000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 427,000.00 |
| Dec 31, 2025 | 427,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Sep 30, 2023 | 150,000.00 |